Playing the India card

Merieux Alliance Group says its acquisition of Shantha Biotechnics Ltd. is intended to provide the French company with a new foothold in Asia. Initially, Merieux says it will simply use its managerial skills to expand Shantha's already profitable business, which consists of selling vaccines and biosimilars for the developing world. But the deal could serve as a springboard for co-development deals with biotech and pharma companies looking to do clinical trials in India, biomanufacturing deals, and, perhaps, development and

Read the full 791 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE